Tag: DurAVR THV
Anteris marks first successful implantation of DurAVR THV heart valve
ASX-listed biotechnology company Anteris Technologies has announced the successful use of its DurAVR THV biomimetic valve in a valve-in-valve (ViV) procedure.Â
Anteris awarded utility patent for novel transcatheter heart valve replacement
Australian biotechnology company Anteris Technologies announced that the US Patent and Trademark Office has issued another utility patent for its novel DurAVR transcatheter heart valve (THV).
Featured Article
A business-led approach to maximising your SAP investment
Manufacturers are responding to the low-growth environment by focusing on digitisation, ESG and portfolio reshaping, transforming into more digital, resilient, and sustainable organisations.
